PRKG2 and melanoma: Based on the fact that PA4 and PA5 increased cell viability in SHSY5Y cells, not expressing PKG2, had no effect on A673 cells, that express only PKG1α, and that the effect is lost upon PKG2 downregulation, it is reasonable to assume that these compounds are able to reduce melanoma cell viability by activating PKG2.